Black Diamond Therapeutics, Inc. Common Stock (BDTX) is a publicly traded Healthcare sector company. As of May 21, 2026, BDTX trades at $3.66 with a market cap of $147.84M and a P/E ratio of 8.81. BDTX moved +20.00% today. Year to date, BDTX is +40.08%; over the trailing twelve months it is +65.90%. Its 52-week range spans $1.20 to $4.94. Analyst consensus is strong buy with an average price target of $10.25. Rallies surfaces BDTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes BDTX SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $3.66 |
| Market Cap | $147.84M |
| P/E Ratio | 8.81 |
| EPS | $0.39 |
| Dividend Yield | 0.00% |
| 52-Week High | $4.94 |
| 52-Week Low | $1.20 |
| Volume | 3.11K |
| Avg Volume | 0 |
| Revenue (TTM) | $70.00M |
| Net Income | $22.37M |
| Gross Margin | 0.00% |
5 analysts cover BDTX: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $10.25.